Fineman M - Search Results

1

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.

Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C. Hollander P, et al. Among authors: fineman m. Diabetes Obes Metab. 2003 Nov;5(6):408-14. doi: 10.1046/j.1463-1326.2003.00295.x. Diabetes Obes Metab. 2003. PMID: 14617226

2

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA. Jolivalt CG, et al. Among authors: fineman m. Diabetes Obes Metab. 2011 Nov;13(11):990-1000. doi: 10.1111/j.1463-1326.2011.01431.x. Diabetes Obes Metab. 2011. PMID: 21635674 Free PMC article.

3

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. Fineman M, et al. Horm Metab Res. 2002 Sep;34(9):504-8. doi: 10.1055/s-2002-34790. Horm Metab Res. 2002. PMID: 12384827 Clinical Trial.

4

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Ratner RE, et al. Among authors: fineman m. Diabet Med. 2004 Nov;21(11):1204-12. doi: 10.1111/j.1464-5491.2004.01319.x. Diabet Med. 2004. PMID: 15498087 Clinical Trial.

5

Glucoregulatory endocrine responses to intermittent exercise of different intensities: plasma changes in a pancreatic beta-cell peptide, amylin.

Kraemer RR, Acevedo EO, Synovitz LB, Durand RJ, Johnson LG, Petrella E, Fineman MS, Gimpel T, Castracane VD. Kraemer RR, et al. Among authors: fineman ms. Metabolism. 2002 May;51(5):657-63. doi: 10.1053/meta.2002.32023. Metabolism. 2002. PMID: 11979402

6

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG. Fineman MS, et al. Metabolism. 2002 May;51(5):636-41. doi: 10.1053/meta.2002.32022. Metabolism. 2002. PMID: 11979398 Clinical Trial.

7

Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes.

Mäkimattila S, Fineman MS, Yki-Järvinen H. Mäkimattila S, et al. Among authors: fineman ms. J Clin Endocrinol Metab. 2000 Aug;85(8):2822-7. doi: 10.1210/jcem.85.8.6721. J Clin Endocrinol Metab. 2000. PMID: 10946889

8

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C. Ratner R, et al. Among authors: fineman ms. Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204. doi: 10.1055/s-2005-837662. Exp Clin Endocrinol Diabetes. 2005. PMID: 15891954 Clinical Trial.

9

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.

Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Taylor K, et al. Among authors: fineman ms. Horm Metab Res. 2005 Oct;37(10):627-32. doi: 10.1055/s-2005-870529. Horm Metab Res. 2005. PMID: 16278786 Clinical Trial.

10

GLP-1 based therapies: differential effects on fasting and postprandial glucose.

Fineman MS, Cirincione BB, Maggs D, Diamant M. Fineman MS, et al. Diabetes Obes Metab. 2012 Aug;14(8):675-88. doi: 10.1111/j.1463-1326.2012.01560.x. Epub 2012 Feb 13. Diabetes Obes Metab. 2012. PMID: 22233527 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results